Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XG-102 for Post-cataract Surgery Inflammation
NCT02235272Phase 3Completed
- Sponsor
- Xigen
- Start
- Sep 2014
- Primary completion
- Dec 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of brimapitide in post-operative inflammation, postoperative pain, sponsored by Xigen. Started Sep 2014; status: completed.
02
Drugs
brimapitide
03
Conditions
post-operative inflammationpostoperative pain
Beyond the preview
Go deeper on NCT02235272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02235272.